Cellectis (ADR) (CLLS)
Develops gene-edited allogeneic CAR-T candidates and manufacturing capabilities.
$1.57
vs last close+0.06 (+3.97%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 9.44% | 9.48M ADS | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 10.56% | 10.60M ADS | |
| 1 holder · as of Dec 12, 2025 | |||
| Other | 80.00% | 80.34M ADS | |
| remainder | |||
100.42M ADS as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (72.34M in the company's Sep 22, 2026 report, 100.42M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
27 holders · 9.48M shares · 3 new positions · 5 increased · 9 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| B Group, Inc. | 3.28M | 3.27% | 0 | Aug 14, 2026 |
| Long Focus Capital Management, LLC | 2.74M | 2.73% | −2.2K | Aug 14, 2026 |
| UBS Asset Management Americas Inc | 2.64M | 2.63% | −533.7K | Aug 13, 2026 |
| Macquarie Management Holdings, Inc. | 226.9K | 0.23% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 225.4K | 0.22% | −116.1K | Aug 7, 2026 |
| Morgan Stanley | 85.5K | 0.09% | −1.3K | Aug 13, 2026 |
| LPL Financial LLC | 84.4K | 0.08% | +70 | Aug 7, 2026 |
| Susquehanna International Group, LLP | 50.5K | 0.05% | −15.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| AstraZeneca Holdings B.V.incl. AstraZeneca PLC | 44.00% | 44.00M | 13D | Jan 24, 2025 |
| Caisse des Depotsincl. Bpifrance Participations S.A., Bpifrance S.A. +2 more | 11.10% | 10.60M | 13D | Dec 12, 2025 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.